Last updated: September 7, 2026
TYSABRI, Biogen’s natalizumab brand, remains one of the largest revenue-generating multiple sclerosis products despite mature-market pressure and the 2023 U.S. launch of the first natalizumab biosimilar, TYRUKO. Revenue has held near the $2 billion-plus level because of durable efficacy, high switching costs, strong physician familiarity, and continued use in patients with highly active relapsing disease. The principal medium-term risks are biosimilar price competition, conversion to subcutaneous administration, and competition from high-efficacy therapies such as OCREVUS, KESIMPTA, and BRIUMVI.
What is TYSABRI and how does it make money?
TYSABRI is natalizumab, a humanized monoclonal antibody that blocks alpha-4 integrin and reduces leukocyte migration across the blood-brain barrier. It is approved for relapsing forms of multiple sclerosis and moderately to severely active Crohn’s disease in patients with inadequate response or intolerance to conventional therapies.
Biogen commercializes TYSABRI globally. The product originated from the Biogen and Elan collaboration, and Biogen acquired Elan’s remaining interest in TYSABRI in 2013 for approximately $3.25 billion. That transaction consolidated global economics and control of the product within Biogen.
TYSABRI generates revenue through:
- Intravenous administration in infusion centers.
- Subcutaneous administration using a prefilled syringe in selected markets.
- Multiple sclerosis treatment, which accounts for the majority of sales.
- Crohn’s disease treatment, which represents a smaller commercial segment.
- Patient-support and risk-management infrastructure that reinforces treatment persistence.
The product carries a boxed warning for progressive multifocal leukoencephalopathy, or PML. Risk-management requirements include patient monitoring and the TOUCH prescribing program in the United States. These controls increase administrative burden but also create infrastructure and clinical familiarity that can support continued use in specialist settings.
How has TYSABRI revenue changed over time?
TYSABRI revenue has been relatively stable compared with Biogen’s older oral multiple sclerosis products. Public company reporting indicates that annual product revenue rose from approximately $2.0 billion in the early 2020s to more than $2.2 billion in the 2022-2023 period, with currency movements and regional pricing affecting reported results [1].
| Fiscal period |
Approximate global TYSABRI revenue |
Main commercial interpretation |
| 2020 |
About $2.0 billion |
Mature but growing high-efficacy franchise |
| 2021 |
About $2.1 billion |
Continued specialist demand |
| 2022 |
About $2.2 billion |
Stable demand despite MS competition |
| 2023 |
About $2.2-$2.3 billion |
Biosimilar entry began in the United States |
| 2024 onward |
Direction depends on biosimilar erosion |
Price, volume, and mix become more important |
TYSABRI’s financial trajectory differs from that of TECFIDERA. TECFIDERA experienced a sharper loss of exclusivity and generic erosion, while TYSABRI has retained stronger revenue because biologic substitution is slower and administration is specialist-driven.
Revenue resilience has several sources:
- TYSABRI is positioned as a high-efficacy therapy for patients with active or aggressive relapsing MS.
- Treatment decisions are influenced by prior disease activity, MRI results, JCV status, and PML risk management.
- Patients who are stable on therapy may be reluctant to switch.
- Infusion-center workflows and neurologist familiarity reduce immediate substitution pressure.
- Subcutaneous TYSABRI expands administration options and may protect some patients from switching to competing products.
The main financial weakness is that the brand has entered a mature phase. Future growth depends less on new patient additions and more on retention, price, geographic expansion, and the ability to defend share against biosimilars and competing high-efficacy agents.
When does TYSABRI lose exclusivity?
TYSABRI’s exclusivity is not governed by one universal date. The relevant protection stack includes regulatory exclusivity, patent rights, pediatric extensions, formulation claims, manufacturing claims, and litigation settlements.
The U.S. biologic reference-product exclusivity period for TYSABRI has expired. The FDA approved TYSABRI in 2004, and the modern U.S. biosimilar pathway under the Biologics Price Competition and Innovation Act became the relevant route for competitors after the reference product’s exclusivity period ended [2].
Patent protection is jurisdiction-specific. Core natalizumab composition and antibody patents have reached late-life status in major markets, while formulation, dosing, administration, manufacturing, and treatment-method claims may have different expiration dates. The commercial consequence is that biosimilar launch timing depends on the enforceable claims remaining in each jurisdiction, not on a single TYSABRI patent expiration date.
What is the Orange Book status of TYSABRI?
TYSABRI is a biologic and is not managed through the small-molecule Orange Book patent-certification framework. The relevant FDA reference-product and biosimilar information is maintained through the Purple Book and the BPCIA regulatory process [3].
A biosimilar applicant does not generally file an Orange Book Paragraph IV certification for TYSABRI. Instead, it follows the BPCIA patent-information exchange and litigation framework under 42 U.S.C. § 262(l).
Which biosimilar is challenging TYSABRI?
TYRUKO, natalizumab-sztn, is the principal U.S. biosimilar competitor. The FDA approved TYRUKO in 2023 for the same major indications as TYSABRI, making it the first natalizumab biosimilar approved in the United States [4].
| Product |
Sponsor |
Active ingredient |
U.S. status |
Commercial significance |
| TYSABRI |
Biogen |
Natalizumab |
Reference biologic |
Established franchise |
| TYRUKO |
Sandoz and Polpharma Biologics |
Natalizumab-sztn |
FDA-approved biosimilar in 2023 |
First direct U.S. biosimilar competitor |
TYRUKO is not a generic version in the traditional small-molecule sense. It is a biosimilar supported by analytical, pharmacokinetic, clinical pharmacology, and comparative immunogenicity data. The FDA approval does not mean that all patients will automatically be substituted at the pharmacy level. Biologic substitution depends on state law, payer policy, prescriber decisions, product contracting, and whether a product has an interchangeable designation.
The biosimilar’s strongest commercial targets are likely to be:
- New starts where physicians and payers prioritize lower cost.
- Patients whose payer requires biosimilar use.
- Infusion providers seeking improved reimbursement economics.
- Health systems operating under biosimilar-preferred formularies.
- Stable patients willing to transition under clinical monitoring.
The most defensible TYSABRI patients are those with strong historical response, complex PML-risk management, established infusion routines, or physician reluctance to change a stable regimen.
What formulation patents protect TYSABRI?
TYSABRI protection has extended beyond the original intravenous product through delivery and formulation development. The subcutaneous presentation received FDA approval in 2023, allowing administration through a prefilled syringe rather than intravenous infusion [5].
Formulation and delivery claims can protect:
- Subcutaneous delivery of natalizumab.
- Dose concentration and injection volume.
- Prefilled syringe configurations.
- Stability and storage conditions.
- Administration intervals and treatment protocols.
- Manufacturing processes for a complex monoclonal antibody.
These rights are commercially relevant even where core antibody patents have expired. A biosimilar approved for the reference product may not automatically replicate every device, presentation, or administration method. The competitive effect depends on the scope and enforceability of each claim and on whether the biosimilar sponsor launches an alternative presentation.
The subcutaneous product also changes TYSABRI’s cost structure. It can reduce infusion-center dependence and improve convenience, but it may face direct competition from self-administered products such as KESIMPTA. Subcutaneous delivery therefore protects the franchise from infusion burden while placing it in a more direct comparison with established home-injection therapies.
How strong is the TYSABRI patent estate?
The TYSABRI patent estate is commercially meaningful but no longer comparable to an early-stage biologic portfolio. Its strength is concentrated in secondary protection and operational barriers rather than a single remaining composition-of-matter monopoly.
| Protection category |
Current strategic value |
| Core antibody and composition claims |
Limited by age and expiry in major markets |
| Formulation claims |
Relevant to specific presentations and stability profiles |
| Subcutaneous administration claims |
Important for defending the newer delivery option |
| Manufacturing claims |
Potentially difficult for biosimilars to design around |
| Method-of-use claims |
Can support selected disease, dosing, or patient populations |
| Regulatory risk controls |
Important commercial barrier, although not patent exclusivity |
The strongest non-patent barriers are clinical and operational. Natalizumab requires careful PML risk management, including JCV antibody testing, treatment duration assessment, MRI monitoring, and patient counseling. A biosimilar can rely on the reference product’s clinical experience, but it must establish physician confidence and payer acceptance.
What patent litigation and settlement issues affect TYSABRI?
TYSABRI biosimilar competition is governed primarily by BPCIA procedures, patent negotiations, and commercial launch arrangements rather than a conventional Paragraph IV dispute. The relevant legal issues include:
- Identification of patents in the Purple Book and related patent exchanges.
- Patent litigation under the BPCIA.
- Launch timing after regulatory approval.
- Settlement terms governing entry dates.
- Scope of any licenses covering formulation, manufacturing, or methods of use.
- Whether a biosimilar launches with intravenous, subcutaneous, or both presentations.
Publicly reported commercial entry of TYRUKO means the market has moved from theoretical biosimilar risk to realized competition. The key question is no longer whether a biosimilar can obtain approval. It is whether it can obtain enough payer preference and physician adoption to produce material price and volume erosion.
How does TYSABRI compare with competing multiple sclerosis drugs?
| Drug |
Company |
Modality |
Competitive position versus TYSABRI |
| TYSABRI |
Biogen |
IV or SC monoclonal antibody |
High efficacy; PML monitoring burden |
| TYRUKO |
Sandoz/Polpharma |
Biosimilar natalizumab |
Lower-cost substitute with reference-product similarity |
| OCREVUS |
Roche |
IV anti-CD20 antibody |
Broad high-efficacy positioning; twice-yearly dosing |
| KESIMPTA |
Novartis |
Monthly self-injected anti-CD20 antibody |
Convenience and home administration |
| BRIUMVI |
TG Therapeutics |
IV anti-CD20 antibody |
Newer high-efficacy competitor with pricing pressure |
| TECFIDERA |
Biogen |
Oral fumarate |
Established oral option but generic competition |
| VUMERITY |
Biogen |
Oral fumarate |
Oral tolerability and lifecycle-management role |
OCREVUS is the most important branded high-efficacy competitor by market presence. KESIMPTA creates greater pressure on TYSABRI’s subcutaneous strategy because both products can be administered outside an infusion center. BRIUMVI adds another anti-CD20 option and may compete through pricing and contracting.
TYSABRI retains an important clinical position because natalizumab has rapid onset, strong efficacy, and an established role in patients requiring high disease control. Its disadvantage is the PML risk-management burden and the need for regular monitoring.
What generic launch risks exist for TYSABRI?
The term “generic launch” is technically inaccurate for TYSABRI. The relevant risk is biosimilar entry. The commercial erosion curve is likely to be slower than for an oral generic but faster than for many older injectable biologics if payers actively promote TYRUKO.
Base-case launch scenario
The base case is gradual share loss rather than immediate collapse:
- Biosimilar adoption begins with new patients and payer-mandated switches.
- Net price declines before major unit-volume erosion.
- Biogen protects part of the franchise through contracting and subcutaneous conversion.
- Neurologists retain TYSABRI for clinically complex or high-risk patients.
- Revenue declines in stages as payer coverage expands.
Downside scenario
A faster erosion scenario would occur if:
- Large commercial insurers place TYRUKO on preferred tiers.
- Medicare and hospital systems adopt biosimilar-first protocols.
- TYRUKO receives or obtains broad substitution support.
- Sandoz prices materially below TYSABRI.
- Physicians become comfortable switching stable patients.
- Competing anti-CD20 products gain further share.
Defensive scenario
TYSABRI could retain a substantial premium if:
- Biogen preserves physician confidence through safety monitoring.
- Subcutaneous delivery improves patient persistence.
- PML-risk management remains a barrier to switching.
- Payers view natalizumab as clinically distinct from anti-CD20 therapies.
- Contracting offsets the biosimilar’s gross-price advantage.
What is TYSABRI’s geographic coverage?
TYSABRI is marketed in the United States, Europe, and other major pharmaceutical markets. Geographic exposure differs by formulation and reimbursement structure.
The United States is the most immediate biosimilar battleground because TYRUKO is approved and commercially available there. Europe has longer experience with biologic competition and centralized regulatory review, but market access remains country-specific. Pricing and substitution are affected by national reimbursement agencies, hospital tenders, prescription rules, and local biosimilar policies.
Emerging-market opportunities are constrained by:
- Complex biologic manufacturing.
- Cold-chain requirements.
- Specialist administration.
- PML monitoring infrastructure.
- Reimbursement limitations.
- Local regulatory requirements.
What is the financial outlook for TYSABRI?
TYSABRI should remain a multibillion-dollar franchise in the near term, but its growth profile has changed from expansion to defense. Revenue depends on the balance between patient retention, biosimilar price pressure, subcutaneous adoption, and competition from high-efficacy MS therapies.
The central financial variables are:
- Biosimilar market share captured by TYRUKO.
- Average selling price and payer rebate intensity.
- Conversion from intravenous to subcutaneous TYSABRI.
- New patient starts versus discontinuations.
- Use in Crohn’s disease.
- Geographic mix and currency effects.
- Cost of patient monitoring and commercial support.
TYSABRI remains strategically valuable to Biogen because it provides durable cash flow, supports the company’s neurology franchise, and has a differentiated high-efficacy profile. Its valuation contribution is lower than during its peak exclusivity period because the product now carries direct biosimilar exposure.
Key Takeaways
- TYSABRI is a mature, high-value natalizumab franchise with annual revenue historically above $2 billion.
- Biogen controls global commercial economics after acquiring Elan’s remaining interest in 2013.
- U.S. biologic exclusivity has expired, and the product is exposed to biosimilar competition.
- TYRUKO, approved by the FDA in 2023, is the first direct U.S. natalizumab biosimilar competitor.
- TYSABRI is governed by the Purple Book and BPCIA framework, not the traditional Orange Book Paragraph IV process.
- Subcutaneous TYSABRI is an important lifecycle-management strategy but competes directly with home-administered MS therapies.
- The principal patent value now lies in formulation, delivery, manufacturing, and method-of-use claims.
- Revenue erosion is more likely to be gradual than immediate, with payer policy determining the speed.
- OCREVUS, KESIMPTA, and BRIUMVI are the main branded high-efficacy competitive threats.
- TYSABRI remains a strong cash-generating asset, but its financial trajectory is shifting from growth to managed decline.
FAQs About TYSABRI Market and Patent Risk
Is TYRUKO interchangeable with TYSABRI?
FDA approval as a biosimilar does not by itself establish automatic pharmacy-level substitution. Interchangeability depends on FDA designation, state substitution laws, payer policy, and prescriber decisions.
Does TYSABRI still have patent protection?
Some formulation, administration, manufacturing, and method-of-use claims may remain relevant by jurisdiction, but core product exclusivity is no longer the primary barrier to biosimilar competition.
Is TYSABRI listed in the Orange Book?
No. TYSABRI is a biologic. Its reference-product and biosimilar status are addressed through the FDA Purple Book and BPCIA procedures.
Will biosimilars eliminate TYSABRI revenue?
No. Biosimilar entry is expected to reduce price and share, but established patients, high-efficacy treatment demand, clinical familiarity, and PML monitoring infrastructure can preserve a substantial branded base.
Which MS therapy poses the greatest threat to TYSABRI?
OCREVUS is the leading broad commercial competitor among high-efficacy therapies. KESIMPTA presents a particularly direct threat to subcutaneous TYSABRI because both products offer non-infusion administration.
References
-
Biogen Inc. (2024). 2023 annual report on Form 10-K. Biogen Inc.
-
U.S. Food and Drug Administration. (2023). TYSABRI (natalizumab) prescribing information. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2023). FDA approves first biosimilar to TYSABRI to treat multiple sclerosis and Crohn’s disease. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2023). FDA approves subcutaneous formulation of TYSABRI. U.S. Department of Health and Human Services.
